Abstract
In 1996, the FDA and DHHS regulations were modified to allow randomized controlled trials in emergency settings with a waiver of informed consent (from patients or surrogates) under specified conditions. The first large multi-center trial under the new regulations was sponsored by Baxter Laboratories, comparing a semi-synthetic hemoglobin to standard care in the initial resuscitation of adults presenting with post-hemorrhagic shock. In addition to the familiar problems that the Data Monitoring Committee had to face, there were new issues, such as reviewing procedures for community disclosure and community consultation, and a heightened sense of scrutiny because of the waiver of traditional consent. The trial was terminated because of higher than expected mortality in the group receiving the experimental treatment. The number of trials initiated under the regulations seems to be less than anticipated, perhaps because the regulatory burden is seens as too onerous.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Biros MH, Lewis RJ, Olson CM, Runge JW, Cummins RO, Fost N. 1995. Informed Consent in Emergency Research: Consensus statement from the Coalition Conference of Acute Resuscitation and Critical Care Researchers. JAMA 273:1283–1287.
Fost N. 1998. Waived consent for emergency research. Am J Law Med 24:163–183.
Fost N. 1998. Ethical dilemmas in medical innovation and research: Distinguishing experimentation from practice. Seminars in Perinatology 22:223–232.
Smithells R. 1975. Iatrogenic hazards and their effects. Postgraduate Medicine 51 (supp 2):39.
Lietman P. Personal communication. 1972.
Protection of Human Subjects. 45 CFR 46:116(d).
Exception from general requirements. 21CFR 50.23(a) (1), 45 CFR 46:116(f).
Protection of Human Subjects: Informed consent and waiver of informed consent requirements in certain emergency research. 61 Federal Register 51498–51533, 1966. Codified at 21 CFR 545, 46, 50.24.
Lewis RJ, Berry DA, Cryer H 3rd, Fost N, Krome R, Washington GR, et al. 2001. Monitoring a clinical trial conducted under the Food and Drug Administration Regulations allowing a waiver of prospective informed consent:The diaspirin cross-linked hemoglobin traumatic hemorrhagic shock efficacy trial. Ann Emerg Med 28:397–404.
Sloan EP, Koenigsberg M, Gens D, Cipolle M, Runge J, Mallory MN, Rodman G Jr. 1999. Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: a randomized controlled efficacy trial. JAMA 282:1857–1864.
Prentice ED, Antonson DL, Leibrock LG, Kelso TK, Sears TD. 1993. IRB review of a Phase II randomized clinical trial involving incompetent patients suffering from severe closed head injury. IRB: A Review of Human Subjects Research 15:1–7.
Fost NC, Robertson JA. 1980. Deferring consent with incompetent patients in an intensive care unit. Irb: A Review of Human Subjects Research 2:5–6.
Abramson NS, Meisel A, Safar P. 1986. Deferred consent: a new approach for resuscitation research on comatose patients. JAMA 255:2466–2471.
Sloan EP, Koenigsberg M, Brunett PH, Bynoe RP, Morris JA, Tinkoff G, Dalsey WC, Ochsner MG. DCLHb Traumatic Hemorrhagic Shock Study Group. 2002. Post hoc mortality analysis of the efficacy trial of diaspirin cross-linked hemoglobin in the treatment of severe traumatic hemorrhagic shock. J Trauma-Injury Infect Crit Care 52:887–895.
Sloan EP. The clinical trials of diaspirin cross-linked hemoglobin (DCLHb) in severe traumatic hemorrhagic shock: the tale of two continents. Intens Care Med. 29:347–349, 2003.
Baren AM, Anicetti JP, Ledesma S, Biros MH, Mahabee-Gittens M, Lewis RJ, et al. 1999. An approach to community consultation prior to initiating an emergency research study incorporating a waiver of informed consent. Acad Emerg Med 6:1210–1215.
Biros MH, 2003. Research Without Consent: Current Status, 2003. Ann of Emerg Med 42:550–564.
Dix ES, Esposito D, Spinosa F, Olson N, Chapman S. 2004. Implementation of Community Consultation for Waiver of Informed Consent in Emergency Research: One Institutional Review Board’s Experience. J Invest Med 52:109–112.
Raju TN. 2004. Waiver of Informed Consent in Emergency Research and Community Disclosures and Consultations. J Invest Med 52:113–116.
Shah AN, Sugarman J. 2003. Protecting Research Subjects Under the Waiver of Informed Consent for Emergency Research: Experiences with Efforts to Inform the Community. Ann Emerg Med 41:72–78.
FDA Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors: Exception from Informed Consent Requirements for Emergency Research [Draft Guidance dated March 30, 2000]. Available at http://www.fda.gov
Kolata G. Ban on Medical Experiments Without Consent Is Relaxed. 1996. NY Times, Nov 5, Section A, page 1, column 3.
Rothman KJ. Michels KB. 1994. The continuing unethical use of placebo controls. N Engl J Med 331:394–398.
Northfield Laboratories Inc. to Receive Defense Appropriation for PolyHeme(R) Development. http://www.northfieldlabs.com (Accessed Oct 3, 2004).
U.S. Navy to Help Fund and Conduct Biopure’s Pivotal Clinical Trial of Hemopure(R) in Trauma. http://www.biopure.com (Accessed Oct 4, 2004).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, Inc.
About this chapter
Cite this chapter
Lewis, R.J., Fost, N. (2006). Monitoring a Clinical Trial With Waiver of Informed Consent: Diaspirin Cross-Linked Hemoglobin for Emergency Treatment of Post—Traumatic Shock. In: DeMets, D.L., Furberg, C.D., Friedman, L.M. (eds) Data Monitoring in Clinical Trials. Springer, New York, NY. https://doi.org/10.1007/0-387-30107-0_21
Download citation
DOI: https://doi.org/10.1007/0-387-30107-0_21
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-20330-0
Online ISBN: 978-0-387-30107-5
eBook Packages: Mathematics and StatisticsMathematics and Statistics (R0)